Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience

Author(s): Alexander Hawlitschka, Veronica Antipova, Oliver Schmitt, Martin Witt, Reiner Benecke, Eilhard Mix, Andreas Wree

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 1 , 2013


Become EABM
Become Reviewer
Call for Editor

Abstract:

The use of botulinum neurotoxins (BoNTs) for therapeutic purposes in neuromuscular disorders and peripheral hypercholinergic conditions as well as in aesthetic medicine is widespread and common. BoNTs are also able to block the release of a wide range of transmitters from presynaptic boutons. Therefore, application of BoNTs directly in the central nervous system (CNS) is currently under study with respect to basic research and potentially as a new therapeutic strategy of neurological diseases. Investigations concentrate on effects of intracerebral and intraspinal application of BoNTs in rodents on the impact on spinal, nuclear, limbic and cortical neuronal circuits. In animal model first promising BoNTinduced therapeutical benefit has been shown in the treatment of pain, epilepsy, stroke and Parkinson’s disease.

Keywords: Botulinum neurotoxin, dementia, epilepsy, hippocampus, ischemia, Parkinson’s disease, spinal cord, striatum

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 1
Year: 2013
Published on: 06 January, 2013
Page: [124 - 130]
Pages: 7
DOI: 10.2174/1389201011314010015

Article Metrics

PDF: 22